Westwood Holdings Group Inc. acquired a new position in AstraZeneca plc (NYSE:AZN) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,218 shares of the company’s stock, valued at approximately $133,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in AZN. Invesco Ltd. boosted its position in shares of AstraZeneca by 213.9% during the second quarter. Invesco Ltd. now owns 5,309,181 shares of the company’s stock worth $219,163,000 after acquiring an additional 3,617,993 shares during the last quarter. Marshall Wace North America L.P. boosted its position in shares of AstraZeneca by 2,528.5% during the second quarter. Marshall Wace North America L.P. now owns 3,013,649 shares of the company’s stock worth $124,403,000 after acquiring an additional 2,898,998 shares during the last quarter. OppenheimerFunds Inc. boosted its position in shares of AstraZeneca by 141.3% during the first quarter. OppenheimerFunds Inc. now owns 4,105,290 shares of the company’s stock worth $165,977,000 after acquiring an additional 2,403,920 shares during the last quarter. GQG Partners LLC boosted its position in shares of AstraZeneca by 72.0% during the first quarter. GQG Partners LLC now owns 5,155,269 shares of the company’s stock worth $207,823,000 after acquiring an additional 2,157,252 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of AstraZeneca by 261.8% during the second quarter. Marshall Wace LLP now owns 2,345,410 shares of the company’s stock worth $96,819,000 after acquiring an additional 1,697,224 shares during the last quarter. 17.52% of the stock is owned by hedge funds and other institutional investors.
AZN has been the subject of a number of research reports. DZ Bank lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, September 3rd. ValuEngine lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Argus upped their target price on shares of AstraZeneca to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Four analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company. AstraZeneca currently has an average rating of “Hold” and an average price target of $45.96.
AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, July 25th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.43. The firm had revenue of $5.72 billion during the quarter, compared to analyst estimates of $5.57 billion. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The business’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the business earned $0.69 EPS. Analysts expect that AstraZeneca plc will post 1.81 earnings per share for the current fiscal year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: How does a dividend reinvestment plan work?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.